MarÃ-a del Valle Palomo Ruiz

List of Publications by Year
in descending order

42 papers	1,686 citations	279798 23 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	3156 citing authors

#	Article	IF	Citations
1	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607.	6.4	20
2	TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimerâ€™s Disease Patients. Biomedicines, 2022, 10, 385.	3.2	3
3	Effect of Clinically Used Microtubule Targeting Drugs on Viral Infection and Transport Function. International Journal of Molecular Sciences, 2022, 23, 3448.	4.1	5
4	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 2021, 178, 1316-1335.	5.4	28
5	CdSe Quantum Dots in Human Models Derived from ALS Patients: Characterization, Nuclear Penetration Studies and Multiplexing. Nanomaterials, 2021, 11, 671.	4.1	2
6	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie, 2021, 133, 19493-19503.	2.0	2
7	Allosteric Modulation of GSK-3Î² as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. International Journal of Molecular Sciences, 2021, 22, 7367.	4.1	5
8	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie - International Edition, 2021, 60, 19344-19354.	13.8	9
9	CdSe quantum dots evaluation in primary cellular models or tissues derived from patients. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 30, 102299.	3.3	7
10	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 2019, 10, 1183-1196.	3.5	37
11	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Molecular Neurodegeneration, 2018, 13, 19.	10.8	28
12	Efficient Assembly of Quantum Dots with Homogenous Glycans Derived from Natural N-Linked Glycoproteins. Bioconjugate Chemistry, 2018, 29, 3144-3153.	3.6	7
13	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 522-526.	5.2	19
14	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 2017, 26, 403-414.	4.1	22
15	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 2017, 7, 43545.	3.3	40
16	Subtly Modulating Glycogen Synthase Kinase 3 Î²: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 2017, 60, 4983-5001.	6.4	52
17	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. Journal of Chemical Neuroanatomy, 2017, 80, 27-36.	2.1	23
18	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 2017, 116, 174-187.	4.1	23

#	Article	IF	Citations
19	Purple-, Blue-, and Green-Emitting Multishell Alloyed Quantum Dots: Synthesis, Characterization, and Application for Ratiometric Extracellular pH Sensing. Chemistry of Materials, 2017, 29, 7330-7344.	6.7	74
20	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opinion on Therapeutic Patents, 2017, 27, 657-666.	5.0	40
21	T cells control the generation of nanomolar-affinity anti-glycan antibodies. Journal of Clinical Investigation, 2017, 127, 1491-1504.	8.2	63
22	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLoS ONE, 2016, 11, e0162723.	2.5	10
23	3,4-Dihydroxyphenylalanine Peptides as Nonperturbative Quantum Dot Sensors of Aminopeptidase. ACS Nano, 2016, 10, 6090-6099.	14.6	23
24	Delivery and Tracking of Quantum Dot Peptide Bioconjugates in an Intact Developing Avian Brain. ACS Chemical Neuroscience, 2015, 6, 494-504.	3.5	67
25	UV and Sunlight Driven Photoligation of Quantum Dots: Understanding the Photochemical Transformation of the Ligands. Journal of the American Chemical Society, 2015, 137, 2704-2714.	13.7	45
26	Photoligation of an Amphiphilic Polymer with Mixed Coordination Provides Compact and Reactive Quantum Dots. Journal of the American Chemical Society, 2015, 137, 5438-5451.	13.7	91
27	Controlling the Architecture, Coordination, and Reactivity of Nanoparticle Coating Utilizing an Amino Acid Central Scaffold. Journal of the American Chemical Society, 2015, 137, 16084-16097.	13.7	22
28	Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. ACS Chemical Neuroscience, 2014, 5, 194-204.	3.5	25
29	Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice. Biological Psychiatry, 2014, 75, 198-206.	1.3	101
30	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 2013, 70, 3449-3462.	5.4	51
31	Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.. ACS Chemical Neuroscience, 2013, 4, 350-360.	3.5	69
32	Dual inhibitor of PDE7 and GSK-3 â€“ VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 2013, 64, 205-214.	4.1	56
33	Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. Journal of Immunology, 2013, 190, 5000-5011.	0.8	71
34	Identification in Silico and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. ACS Chemical Neuroscience, 2012, 3, 793-803.	3.5	24
35	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Journal of Neurochemistry, 2012, 122, 1193-1202.	3.9	15
36	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	6.4	76

#	Article	IF	Citations
37	Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 2012, 3, 963-971.	3.5	139
38	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3Î² (GSK-3Î²) and phosphodiesterase 7 (PDE7) inhibitors: Determination of bloodâ€“brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences, 2012, 45, 677-684.	4.0	30
39	Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 2011, 54, 8461-8470.	6.4	91
40	The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy. Current Medicinal Chemistry, 2011, 18, 3028-3034.	2.4	28
41	Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 2011, 54, 4042-4056.	6.4	84
42	PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 2011, 6, e15937.	2.5	59